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Halifax, Nova Scotia, CanadaAbstractThe impact of multimorbidity on patients with community-acquired pneumonia has not been well characterised. Thus, our aim was to explore
the relationship between multimorbidity and adverse events within 90 days of discharge. Data were prospectively collected for a population-
based cohort of all adults discharged from any of the seven emergency departments (ED) or six hospitals in Edmonton (Alberta, Canada) with
community-acquired pneumonia. Multivariable Cox regression models were used to examine the independent association between
multimorbidity (deﬁned as two or more chronic conditions) and subsequent 90-day mortality, hospitalisation, or ED visits after treatment
of pneumonia. The cohort included 5565 patients, mean age was 57 years (SD 20), 54% were male, and 59% were treated as outpatients;
1602 (29%) patients had multimorbidity. Within 90 days, 255 (5%) patients died, 1205 (22%) were hospitalised, 1280 (23%) died or were
hospitalised, and 2049 (37%) were admitted to the ED. The presence of multimorbidity was independently associated with an increased
risk of death or hospitalisation within 90 days (37% vs. 17% for those without multimorbidity, adjusted hazard ratio: 1.43, 95%
conﬁdence interval: 1.26 to 1.62) as well as ED visits (45% vs. 34%, adjusted hazard ratio: 1.40, 95% conﬁdence interval: 1.26 to 1.56).
Multimorbidity was present in one-third of all patients with pneumonia in our study, and it was independently associated with death,
hospitalisation, or return to ED within 90 days of discharge. Our ﬁndings suggest that multimorbidity is strongly related to prognosis and
should be considered when making site-of-care decisions in the ED or deciding upon readiness for discharge.
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E-mail: deurich@ualberta.caIntroductionMultimorbidity, an emerging concept most commonly deﬁned as
the coexistence of two or more chronic health conditions within
an individual, is very common. Fully 25% of all adults seeking
medical care, and about three in every four individuals aged 65
years or older, are considered to be multimorbid [1]. This is aMicrobiol Infect 2015; 21: 264.e7–264.e13
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.11.002major concern for governments and health care systems given
that patients with multimorbidity represent an increasing burden
on the health care system in terms of both cost and utilisation
[2–4]. Multimorbid patients are more likely to die prematurely,
have poorer quality of life, and experience a greater loss of
physical functioning than those without multimorbidity [5–7].
Multimorbidity is conceptually distinct from comorbidity in that
comorbidity is most often deﬁned as another chronic condition
in relation to the chronic disease of interest, whereas multi-
morbidity is meant to represent any co-occurrence of two or
more chronic conditions within a person [8].
Historically, researchers have tended to focus on the study
and treatment of discrete disease states in those hospitalised forious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Weir et al. Multimorbidity in pneumonia 264.e8conditions such as heart failure, chronic obstructive pulmonary
disease (COPD), and diabetes; this tendency is particularly
pronounced in the study of acute conditions such as pneu-
monia. However, several chronic diseases cluster in patients
with community-acquired pneumonia (CAP) [9], thus it pro-
vides an ideal condition to study the impact of multimorbidity
on outcomes after hospital or emergency department (ED)
discharge. CAP is one of the most common acute conditions in
adults (particularly in elderly persons) and is associated with
high rates of hospitalisation and mortality [10,11]. Furthermore,
some studies suggest that CAP may be associated with long-
term sequelae such as ongoing respiratory problems [12],
cardiac complications, or other adverse effects [13], and fully
half of adults who survive a pneumonia hospitalisation will die
within 5 years [14].
Even though the impact of single comorbid conditions on
downstream adverse events in patients with CAP has been
studied (e.g. the role of COPD in patients with CAP), as has
the effect of multimorbidity in patients with chronic condi-
tions such as diabetes or heart failure, there is scarce litera-
ture on the impact of multimorbidity in patients with acute
conditions. Research that has been conducted in this subject
area is scarce, involves a diverse group of acute conditions
(with very few completed in CAP), and has produced con-
ﬂicting results. Furthermore, although the Pneumonia Severity
Index (PSI) includes some chronic conditions in its calculation,
evaluating the independent effect of multimorbidity is
important given that age largely drives the PSI score and that
often many of the other criteria (e.g. laboratory data) are not
immediately available to clinicians at the time of triage (site-
of-care) decisions [15–17]. Therefore, our aim was to
explore the relationship between multimorbidity and adverse
health outcomes (death, hospitalisation, ED visits) in a
population-based cohort of adults who survived an episode of
CAP.Materials and methodsPatients and setting
Our prospective cohort has been previously described in
detail [14]. In brief, data were collected prospectively for all
patients 17 years or older with CAP who visited any of the six
hospitals (inpatients) or were managed and discharged from
the seven EDs (outpatients) within Edmonton, Alberta, Can-
ada, from 2000 to 2002. All patients were treated according to
a previously validated CAP critical pathway [18,19]. CAP was
deﬁned as the presence of radiographic evidence of pneumonia
determined by the treating physician and at least two of the
following signs or symptoms: cough (productive orClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Innonproductive), pleurisy, shortness of breath, temperature
>38°C, and crackles or bronchial breathing on auscultation.
Patients with tuberculosis or cystic ﬁbrosis or who were
immunocompromised, pregnant or nursing, or who had been
hospitalised in the previous 14 days were excluded from the
cohort. In addition, we excluded all patients who died during
the initial CAP episode and those with health care–associated
pneumonia, such as nursing home residents. The study was
approved by the Health Ethics Review Board of the University
of Alberta (Edmonton, Alberta, Canada; approval
#Pro00004999).
Measurements
Using standardised abstraction forms, trained research nurses
collected all data, including sociodemographic variables,
comorbidities, and prescription medication use in the week
prior to admission, as well as functional status, smoking status,
and laboratory data. In addition, the well-validated PSI was
calculated for each patient at the time of presentation. The PSI
is a measure of pneumonia-speciﬁc illness severity designed to
predict 30-day all-cause mortality and is based on de-
mographics, comorbidities, physical ﬁndings and laboratory
tests [20]. Although designed to predict 30-day mortality, we
and others have demonstrated that the PSI can be used for risk-
adjusted mortality for up to 5 years [14] and that the PSI is
independently associated with both short- and long-term hos-
pital readmissions [14,21].
Multimorbidity
Patients were considered multimorbid if they had at least two
chronic conditions documented during their episode of CAP.
Multimorbidity status was ascertained by determining the
number (0, 1, 2, 3 or more) of existing physician-assigned di-
agnoses documented during the initial CAP presentation ac-
cording to medical records and patient or proxy interviews.
Chronic conditions included a history of any nonskin cancer,
chronic liver disease, heart failure, stroke, ischemic heart dis-
ease, renal disease (including chronic kidney disease and end-
stage renal disease requiring dialysis), asthma, COPD, dia-
betes, seizures, and neuropsychiatric disorders (see e-Appendix
1 for distribution of chronic conditions). These conditions were
included because they are collectively components of the PSI as
well as the Charlson Comorbidity Index, Elixhauser Index, and
Mortality Risk Score.
Outcomes
Our primary outcome of interest was all-cause death or hos-
pital admission within 90 days of discharge from hospital or the
ED. Our secondary outcomes included the components of the
primary outcome (death or hospital admission separately) asfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 252.e5–252.e8
TABLE 1. Characteristics of 5565 patients after an episode of
community-acquired pneumonia stratiﬁed by multimorbidity
status
Characteristic
Full cohort
(n [ 5565)
Fewer than
two chronic
conditions
(n [ 3963)
Multimorbidity
(two or more
chronic conditions)
(n [ 1602) p Valuea
Age
(mean ± SD)
56.8 (20.3) 52.2 (19.6) 70.8 (14.2) <0.001
Age 65 years
n (%)
2240 (40.3) 1101 (27.8) 1139 (71.1) <0.001
Male
n (%)
2977 (53.5) 2088 (52.7) 889 (55.5) 0.057
Outpatient
n (%)
3283 (59.0) 2824 (71.3) 459 (28.7) <0.001
Functional
independence
n (%)
5054 (90.8) 3624 (91.5) 1430 (89.3) 0.01
Acute Pneumonia
Severity index
(mean ± SD)
14.7 (21.0) 10.3 (17.1) 25.5 (25.4) <0.001
Pneumonia
Severity Index
(mean ± SD)
71.7 (37.5) 58.6 (31.0) 103.9 (32.2) <0.001
aThe p value is for the difference between fewer than two chronic conditions and
two or more chronic conditions.
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ensures that any adverse events observed might still be plausibly
related to the original pneumonia episode and because this
timeframe has been commonly used by others [22,23]. All
postdischarge data were ascertained using multiple linked and
well-validated Alberta provincial administrative databases [24].
The quality and validity of these databases are routinely checked
both provincially and federally with processes to resolve data
issues where identiﬁed.
Analysis
Time-to-event data were plotted and calculated using Kaplan-
Meier curves. Multivariable Cox proportional hazards models
were used to estimate the independent association between
multimorbidity (deﬁned as 2 or more chronic conditions) and
our outcomes of interest adjusted for age, sex, site-of-care for
the index CAP (inpatient or outpatient), premorbid functional
status (deﬁned as completely independent in ambulation and
mobility vs. not) and the PSI calculated at the time of presen-
tation. Because the PSI score includes points for patients with
the presence of certain chronic conditions (any nonskin cancer,
any degree of chronic kidney disease, heart failure, chronic liver
disease, and stroke), we excluded these point values and
recalculated an acute PSI (aPSI) score (based on physical ex-
amination, laboratory, and radiographic ﬁndings at presenta-
tion) as previously done by others [21]. Patients were followed
up for 90 days after their index CAP discharge from hospital or
ED until death, ﬁrst hospitalisation, or emigration from the
province. Proportional hazard assumptions were veriﬁed using
Schoenfeld Residuals, and no appreciable violations were
observed [25]. No clinically and statistically important ﬁrst-
order interaction terms were noted, and none were included
in ﬁnal models.
Sensitivity analyses
First, we evaluated the impact of the total number of comorbid
conditions by further categorising patients as having only one
chronic condition, only two chronic conditions, or three or
more chronic conditions compared to having no chronic
conditions. Second, we determined whether multimorbidity
was prognostic in all age categories, including in those under
the age of 65 and those 65 and over. Next, we conducted
additional analyses in which we followed up patients from time
of hospital admission to allow for the inclusion of patients who
died during the initial CAP encounter. This is distinct from our
primary analysis, in which patients were followed up from
hospital discharge, resulting in the exclusion of those who died
in hospital. Fourth, we evaluated whether or not the inclusion
of the unmodiﬁed PSI (i.e. the conventional PSI, which includes
comorbidity points for some conditions) would result in anyClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectchanges to our main results. All analyses were conducted using
STATA/SE version 12.0 (Stata Corp College Station, TX,
USA).ResultsPatient characteristics
Of the 6874 patients with CAP, 321 (5%) patients died in
hospital and were excluded from primary analyses, as were 367
(6%) patients who could not be linked to administrative data-
bases and 621 (10%) nursing home residents, resulting in a ﬁnal
cohort of 5565 patients. Mean age was 57 (SD 20) years, 2240
(40%) were 65 years of age or older, 2977 (54%) were male,
3283 (59%) were treated as outpatients (i.e. treated for CAP
and discharged to the community from the ED), 5054 (91%)
were functionally independent prior to their CAP, mean PSI
was 75 (SD 39), and 1649 (30%) had severe (PSI class IV or V)
pneumonia. The mean aPSI was 15 (SD 21) after the subtraction
of points for age and comorbidities.
Prevalence and correlates of multimorbidity
Overall, 1602 (29%) patients had multimorbidity as we deﬁned
it. Speciﬁcally, 2378 (43%) patients had no chronic conditions,
1585 (29%) had one chronic condition, 831 (15%) had two
chronic conditions, and 771 (14%) had three or more chronic
conditions. Compared to those without morbidity, patients
with multimorbidity were signiﬁcantly older, more likely to be
treated as inpatients, less likely to be functionally independent
and tended to have more severe pneumonia (Table 1).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 252.e5–252.e8
TABLE 3. Unadjusted and adjusted hazard ratios for all-cause
death or hospital admission within 90 days according to
multimorbidity count
90-day Outcomes
Number of
chronic
conditions
Unadjusted HR
(95% CI)
Adjusted HRa
(95% CI)
p value
for
trendb
All-cause death or
hospital admission
0 Reference Reference <0.001
1 2.23 (1.91–2.59) 1.68 (1.43–1.97)
2 3.09 (2.62–3.65) 1.90 (1.58–2.28)
3+ 4.08 (3.48–4.79) 2.13 (1.76–2.58)
All-cause death 0 Reference Reference <0.001
1 4.39 (2.86–6.76) 2.76 (1.77–4.33)
2 7.31 (4.71–11.33) 3.36 (2.09–5.39)
3+ 9.00 (5.85–13.86) 3.34 (1.88–5.43)
All-cause hospital
admission
0 Reference Reference <0.001
1 2.18 (1.87–2.55) 1.66 (1.41–1.96)
2 3.01 (2.54–3.58) 1.88 (1.56–2.27)
3+ 3.97 (3.37–4.67) 2.13 (1.75–2.58)
Emergency
department visit
0 Reference Reference <0.001
1 1.23 (1.10–1.37) 1.28 (1.14–1.43)
2 1.44 (1.27–1.63) 1.52 (1.32–1.75)
3+ 1.60 (1.41–1.82) 1.75 (1.51–2.05)
HR, hazard ratio.
aHR is adjusted for age, sex, acute Pneumonia Severity Index, setting, functional
status.
bFor trend across increasing number of chronic conditions.
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index CAP event
Overall, of the 5565 patients who survived their initial hospi-
talisation or ED assessment, 255 (5%) subsequently died and
1101 (22%) were (re)admitted to hospital within 90 days.
Multimorbidity was associated with signiﬁcant increases in the
risk of death or hospitalisation within 90 days (37% vs. 17%,
adjusted hazards ratio [aHR]: 1.43, 95% CI: 1.26 to 1.62) as well
as for each endpoint separately (7% vs. 1%, aHR: 3.02, 95% CI:
1.98 to 4.62 for death within 90 days of CAP discharge; 35% vs.
16%, aHR: 1.43, 95% CI: 1.26 to 1.63 for hospital admission
within 90 days of CAP discharge) (Table 2).
ED visit after index CAP event
Overall, 2049 (37%) of those with pneumonia who were dis-
charged from hospital or ED presented back to an ED within 90
days. Compared to those who did not have multimorbidity,
those with multimorbidity were 40% more likely to visit the ED
within 90 days of discharge (45% vs. 34%, aHR: 1.40, 95% CI:
1.26 to 1.56).
Sensitivity analyses
First, in terms of dose response, the existence of each chronic
condition was associated with a graded and increased risk of
death or hospital admission, death alone, hospital admission
alone, and ED visits (adjusted p value for trends all <0.001,
Table 3, Fig. 1). Indeed, the existence of three or more chronic
conditions in patients with CAP was associated with a twofold
increased risk in 90-day death or all-cause hospitalisation when
compared to those without any chronic conditions (42% vs.
12%, aHR: 2.13, 95% CI: 1.76 to 2.58). Second, we found that
multimorbidity was signiﬁcantly associated with prognosis in
both young (<65 years aHR: 1.71, 95% CI: 1.39 to 2.11) and old
(65 years aHR: 1.31, 95% CI: 1.13 to 1.52) alike (p 0.02 for
interaction). Additionally, our results were nearly identical to
our main study ﬁndings after including patients who died during
the initial CAP event, in that multimorbidity was still associatedTABLE 2. Unadjusted and adjusted hazard ratios for primary and se
status
90-day outcomes
Multimorbidity (two or more
chronic conditions)
Crude ev
n (
All-cause death or hospital admission Absent 685
Present 595
All-cause death Absent 28
Present 227
All-cause hospital admission Absent 649
Present 556
Emergency department visit Absent 1336
Present 713
HR, hazard ratio.
aHR is adjusted for age, sex, acute Pneumonia Severity Index, setting, functional status.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inwith a 38% increased risk of death or hospital admission (aHR:
1.38, 95% CI: 1.22 to 1.55). Last, inclusion of the unmodiﬁed PSI
(which contained points for several chronic conditions) atten-
uated the relationships observed, although multimorbidity was
still independently associated with a 14% relative increase in the
risk of death or hospital admission (aHR: 1.14, 95% CI: 1.00 to
1.30, p 0.045).DiscussionIn our large population-based cohort of CAP patients, 29% of
patients had multimorbidity as currently deﬁned. We found
that multimorbidity was associated with a 20% absolute (or
40% relative) increase in risk of death or hospital admission 90
days after discharge from the CAP index event. Furthermore,
a strong graded relationship existed between the number ofcondary outcomes within 90 days according to multimorbidity
ent rate
%)
Unadjusted HR
(95% CI) Adjusted HRa (95% CI)
p Value for
adjusted HR
(17.3) Reference Reference
(37.1) 2.41 (2.16–2.69) 1.43 (1.26–1.62) <0.001
(1.2) Reference Reference
(7.1) 6.25 (4.22–9.30) 3.02 (1.98–4.62) <0.001
(16.4) Reference Reference
(34.7) 2.38 (2.12–2.66) 1.43 (1.26–1.63) <0.001
(33.7) Reference Reference <0.001
(44.5) 1.39 (1.27–1.52) 1.40 (1.26–1.56)
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 252.e5–252.e8
FIG. 1. Risk of death or hospital admission for 5565 patients 90 days
after discharge for an episode of community-acquired pneumonia by
multimorbidity status.
264.e11 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIcomorbidities and adverse outcomes. Indeed, although mul-
timorbidity is often classiﬁed as two or more chronic condi-
tions, we observed that in the case of pneumonia, even the
presence of one chronic condition was associated with
signiﬁcantly increased rates of adverse events. To our
knowledge, our study is one of the ﬁrst to explore multi-
morbidity in the setting of pneumonia; whether or not our
ﬁndings can be generalised to other acute illness episodes is
not yet known.
It is important to point out that although the PSI includes a
weighted score for some chronic conditions [14], we found
that the number of chronic conditions patients had indepen-
dently predicted short-term adverse outcomes even after
adjustment for PSI scores. This may be especially important to
consider in settings such as the ED, where site-of-care and
other triage decisions must be made quickly and often without
the availability of a complete medical history and all needed
laboratory data. In addition, the PSI requires weighting the
scores of speciﬁc comorbidities, whereas other triage risk
scores such as the CURB-65 (based on confusion, urea levels,
respiratory rate, blood pressure and age), CTAS (Canadian
Triage and Acuity Scale), SOAR (based on systolic blood
pressures, oxygenation, age and respiratory rate) and SMART-
COP (based on blood pressure, multilobar involvement, al-
bumin levels, respiratory rate, tachycardia, confusion,
oxygenation and PH) do not even account for chronic con-
ditions. Indeed, even after adjustment for the regular PSI,
multimorbidity was still associated with approximately a 14%
increased risk of death or hospital admission, suggesting that
even a simple count of chronic conditions is prognostically
relevant.
Although our study has several strengths, including the
evaluation of both inpatients and outpatients, a large
population-based sample, and detailed clinical data collected byClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectchart review rather than just administrative records, there are a
few limitations. First, this was an observational study and re-
sidual confounding is always a potential issue with observational
studies. Considering the richness of our data source, however,
we were able to adjust for a number of important patient-level
confounders, including the well-validated PSI risk score. Second,
we were unable to identify changes in clinical parameters over
time; however our follow-up time was relatively short, so this
should not be important. Further, it is important to acknowl-
edge our choice to refer to the construct multimorbidity rather
than comorbidity. In studying acute disease leading to hospital
admission (such as pneumonia), there is no particular chronic
disease of principal interest because the admission itself was not
related to the exacerbation of a pre-existing chronic condition.
Therefore, we used multimorbidity to refer to the co-
occurrence of multiple chronic medical conditions (two or
more) within one person as opposed to just the addition of a
chronic condition in reference to a chronic condition of in-
terest. This deﬁnition, however, does not permit any relative
weighting of the importance of particular conditions (e.g. cur-
rent heart failure vs. remotely treated colorectal cancer) or the
severity of any speciﬁc condition (e.g. well-controlled diet-
treated diabetes vs. diabetes requiring an insulin pump).ConclusionsIn summary, in our study of patients with pneumonia, multi-
morbidity was very common and provided important prognostic
information for the postdischarge period. Although the man-
agement of a life-threatening acute illness always takes clinical
priority, our ﬁndings suggest that when managing or making site-
of-care decisions for patients with pneumonia, more attention
should be paid to apparently unrelated comorbidities and mul-
timorbidity—given the strong association with short-term
adverse events, perhaps these chronic diseases are more
related than previously appreciated and need to be considered
when deciding on readiness for discharge to the community.Transparency declarationNo potential conﬂict of interest exists with any companies or
organisations whose projects or services may be discussed in
this article. The sponsors had no role in the design of the study,
the collection and analysis of the data, or the preparation of the
manuscript. Dr. Eurich is the guarantor of the manuscript and
takes responsibility for the integrity of the dataset and the ac-
curacy of the analysis. All authors have participated in con-
ducting the analysis, writing, and approval of this manuscript.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 252.e5–252.e8
CMI Weir et al. Multimorbidity in pneumonia 264.e12e-Appendix 1. Distribution and prevalence of
chronic conditions at time of community-
acquired pneumonia episodeChronic conditiona
Crude
number
All patients with
community-acquired
pneumonia, %
(n [ 5565)
Patients with
multimorbidity, %
(n [ 1602)
Nonskin cancer 487 8.8 30.4
Chronic liver disease 125 2.3 7.8
Heart failure 432 7.8 27.0
Stroke 290 5.2 18.1
Ischemic heart disease 1071 19.2 66.9
Renal diseaseb 352 6.3 21.9
Asthma 732 13.2 45.7
Chronic obstructive
pulmonary disease
921 16.7 57.5
Diabetes 569 10.2 35.5
Seizure 124 2.2 7.7
Neuropsychiatric
disorder
428 7.7 26.7
aChronic condition categories are not mutually exclusive; individuals can have more
than one chronic condition.
bIncludes both chronic kidney disease and end-stage renal disease requiring dialysis.e-Appendix 2. Independent predictors of all-
cause death or hospital admission in 90 days:
Cox Proportional Hazards Model for primary
outcomeMultivariable
adjusted HR
95% Conﬁdence
interval
p value for
adjusted HR
Multimorbidity 1.42 1.26–1.62 <0.001
Age 65 1.70 1.50–1.92 <0.001
Male 1.01 0.90–1.13 0.87
1–point increase in
acute Pneumonia
Severity Index
1.01 1.01–1.02 <0.001
Outpatient 0.80 0.69–0.92 0.002
Not independent 1.51 1.23–1.79 <0.001
HR, hazard ratio.
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